DDInter927 DDInter1127
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture.
Measles virus vaccine live attenuated {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracosactide
Measles virus vaccine live attenuated {u} may lead to a major life threatening interaction when taken with {v} Talazoparib
Measles virus vaccine live attenuated {u} may lead to a major life threatening interaction when taken with {v} Tositumomab
Measles virus vaccine live attenuated may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Talazoparib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Tositumomab